Anebulo Pharmaceuticals Reports Q1 2026 Financial Results
I'm PortAI, I can summarize articles.
Anebulo Pharmaceuticals reported Q1 2026 financial results, with operating expenses of $2.3 million and a net loss of $2.2 million. The company has $10.4 million in cash reserves. Anebulo commenced a Phase 1 trial for its drug selonabant, targeting cannabis-induced toxicity in children, supported by a grant from the National Institute on Drug Abuse. The company is exploring strategic alternatives, including a potential reverse stock split, to address unmet needs in cannabis toxicity treatments.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments